Siegel R D, Schiffman F J
Miriam Hospital, Providence, RI 02906.
Chest. 1990 Aug;98(2):507. doi: 10.1378/chest.98.2.507.
Bleomycin administered intrapleurally has been demonstrated to be an effective sclerosing agent. The lack of morbidity associated with its use has made it an attractive alternative to other available agents. Pharmacologic data indicate that (1) intracavitary bleomycin is systemically absorbed, and (2) the plasma half-life of bleomycin increases exponentially with renal failure. We report the findings in a patient with renal failure who experienced alopecia and significant mucositis following sclerotherapy. We suspect this systemic toxicity resulted from intrapleural bleomycin and suggest that this treatment be used with caution in patients with renal dysfunction.
胸膜内注射博来霉素已被证明是一种有效的硬化剂。使用该药物时发病率较低，这使其成为其他现有药物颇具吸引力的替代选择。药理学数据表明：（1）腔内注射的博来霉素会被全身吸收；（2）博来霉素的血浆半衰期会随着肾衰竭呈指数增长。我们报告了一名肾衰竭患者在硬化治疗后出现脱发和严重粘膜炎的情况。我们怀疑这种全身毒性是由胸膜内注射博来霉素所致，并建议在肾功能不全患者中谨慎使用这种治疗方法。
